Restoring lysosomal proteostasis reverses steatohepatitis and fibrosis in experimental MASH
Abstract
Metabolic dysfunction-associated steatohepatitis (MASH) is characterized by progressive inflammation and fibrosis. Left untreated, MASH can progress to cirrhosis, hepatocellular carcinoma, and liver failure. MASH has become the leading indication for liver transplantation worldwide. While global prevalence is increasing, effective and mechanism-oriented therapies remain limited. Based on earlier independent studies showing that lysosomes are impaired and autophagy is dysregulated in MASH, our aim was to finely map autophagy dysfunction in an experimental mouse model of MASH and explore the capacity of a modulator of chaperonemediated autophagy to mitigate the course of the disease. We effectively identified a number of markers whose expression was pathologically increased or decreased in various autophagy pathways. In vivo, pharmacological modulation with the phosphopeptide P140 -currently evaluated in phase III-clinical trials for lupuscorrected the expression of some of these markers and restored lysosomal and mitochondrial autophagy programs. It reduced steatohepatitis and fibrosis, and improved systemic inflammatory features without, however, broadly correcting metabolic parameters. Mechanistically, consistent with its established HSPA8 interaction, P140 restored lysosomal/autophagy markers, supporting modulation of this proteostasis network. Our data indicate that this pharmacological restoration of lysosomal proteostasis engages key transcriptional regulators (Mediator complex), leading to the selective remodeling of pro-fibrotic and inflammatory pathways. Collectively, we identified a coordinated disruption of lysosomal quality control networks across multiple autophagy pathways in a validated mouse model of advanced MASH. We established lysosomal autophagy as a druggable vulnerability in MASH and support therapeutic repositioning of P140 as a safe strategy to counter progressive liver diseases.
Related
- Inflammatory proteostasis reprogramming creates a lysosomal bottleneck for microglial aggregate clearance
- Targeting Nitric Oxide Synthase 2 Reverses Learning Deficits in an Oligodendrocyte-Focused Model of Costello Syndrome
- Targeting hypoxia-responsive miR-155-5p and miR-210-3p restores alveolar regeneration and reverses pulmonary fibrosis
- ARID5A Is a PERK-Dependent Effector of the Endoplasmic Reticulum Stress Response That Protects Against Steatohepatitis
- Quantum Dot-Based Non-invasive Monitoring of Sinusoidal Endothelial Scavenger Function in Steatohepatitis
BibTeX
@article{mastrippolito2026restoring,
title = {{Restoring lysosomal proteostasis reverses steatohepatitis and fibrosis in experimental MASH}},
author = {Dylan Mastrippolito and Lauriane Gur and Malia Lasalo and Lara El Kaakour and Cindy Verdot and Franck Coste and Sébastien Blaise and Sylviane Muller},
journal = {Pharmacological Research},
year = {2026},
month = sep,
doi = {10.1016/j.phrs.2026.108427},
url = {https://hal.science/hal-05738754v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Restoring lysosomal proteostasis reverses steatohepatitis and fibrosis in experimental MASH
AU - Dylan Mastrippolito
AU - Lauriane Gur
AU - Malia Lasalo
AU - Lara El Kaakour
AU - Cindy Verdot
AU - Franck Coste
AU - Sébastien Blaise
AU - Sylviane Muller
PY - 2026
DA - 2026/09/04
JO - Pharmacological Research
DO - 10.1016/j.phrs.2026.108427
UR - https://hal.science/hal-05738754v1
AB - Metabolic dysfunction-associated steatohepatitis (MASH) is characterized by progressive inflammation and fibrosis. Left untreated, MASH can progress to cirrhosis, hepatocellular carcinoma, and liver failure. MASH has become the leading indication for liver transplantation worldwide. While global prevalence is increasing, effective and mechanism-oriented therapies remain limited. Based on earlier independent studies showing that lysosomes are impaired and autophagy is dysregulated in MASH, our aim was to finely map autophagy dysfunction in an experimental mouse model of MASH and explore the capacity of a modulator of chaperonemediated autophagy to mitigate the course of the disease. We effectively identified a number of markers whose expression was pathologically increased or decreased in various autophagy pathways. In vivo, pharmacological modulation with the phosphopeptide P140 -currently evaluated in phase III-clinical trials for lupuscorrected the expression of some of these markers and restored lysosomal and mitochondrial autophagy programs. It reduced steatohepatitis and fibrosis, and improved systemic inflammatory features without, however, broadly correcting metabolic parameters. Mechanistically, consistent with its established HSPA8 interaction, P140 restored lysosomal/autophagy markers, supporting modulation of this proteostasis network. Our data indicate that this pharmacological restoration of lysosomal proteostasis engages key transcriptional regulators (Mediator complex), leading to the selective remodeling of pro-fibrotic and inflammatory pathways. Collectively, we identified a coordinated disruption of lysosomal quality control networks across multiple autophagy pathways in a validated mouse model of advanced MASH. We established lysosomal autophagy as a druggable vulnerability in MASH and support therapeutic repositioning of P140 as a safe strategy to counter progressive liver diseases.
SN - 1043-6618
SN - 1096-1186
ER -